Literature DB >> 9744316

Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.

T Torimura1, M Sata, T Ueno, M Kin, R Tsuji, K Suzaku, O Hashimoto, H Sugawara, K Tanikawa.   

Abstract

Vascular endothelial growth factor is a potent direct-acting angiogenic factor. Early in hepatocarcinogenesis, hepatocellular carcinomas do not show hypervascularity; at later stages, they require abundant arterial blood flow. We investigated the role of vascular endothelial growth factor in hepatocellular carcinoma arterialization. We studied 51 patients with hepatocellular carcinoma. All patients had undergone hepatic arteriography. Vascular endothelial growth factor expression was investigated by immunohistochemistry (n = 51) and in situ hybridization (n = 13), and the changes in vascular endothelial growth factor expression were evaluated in relation to tumor differentiation and changes in tumor vascularity. The expression of vascular endothelial growth factor isoforms in hepatocellular carcinomas was also analyzed by reverse transcriptase-polymerase chain reaction (n = 10). Vascular endothelial growth factor expression was detected in hepatoma cells and hepatic stellate cells, and increased vascular endothelial growth factor expression was associated with tumor dedifferentiation. Vascular endothelial growth factor expression in hypervascular hepatocellular carcinomas was greater than in those not showing hypervascularity. The major vascular endothelial growth factor isoforms expressed in hepatocellular carcinoma were 121 and 165. These findings indicate that vascular endothelial growth factors 121 and 165 play a critical role in the process of angiogenesis in hepatocellular carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744316     DOI: 10.1016/s0046-8177(98)90205-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  48 in total

Review 1.  Liver metastases: Microenvironments and ex-vivo models.

Authors:  Amanda M Clark; Bo Ma; D Lansing Taylor; Linda Griffith; Alan Wells
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-06

2.  Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators.

Authors:  Kalman Kovacs; David Bell; Geoffrey W Gardiner; R John Honey; Jeannette Goguen; Fabio Rotondo
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

4.  Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study.

Authors:  Dina Sabry; Omayma O Abdelaleem; Amani M El Amin Ali; Rehab A Mohammed; Nehal D Abdel-Hameed; Amira Hassouna; Warda A Khalifa
Journal:  Mol Biol Rep       Date:  2019-02-01       Impact factor: 2.316

5.  Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a.

Authors:  Jianguo Bai; Jianfei Wu; Ruifeng Tang; Chao Sun; Junwei Ji; Zhaolin Yin; Guangjun Ma; Wei Yang
Journal:  Invest New Drugs       Date:  2019-04-11       Impact factor: 3.850

6.  Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).

Authors:  Hisashi Hidaka; Namiki Izumi; Takeshi Aramaki; Masafumi Ikeda; Yoshitaka Inaba; Kazuho Imanaka; Takuji Okusaka; Susumu Kanazawa; Shuichi Kaneko; Shinichi Kora; Hiroya Saito; Junji Furuse; Osamu Matsui; Tatsuya Yamashita; Osamu Yokosuka; Satoshi Morita; Hitoshi Arioka; Masatoshi Kudo; Yasuaki Arai
Journal:  Med Oncol       Date:  2019-05-03       Impact factor: 3.064

Review 7.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

8.  Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma.

Authors:  L Chen; Z Yang; G Wang; C Wang
Journal:  J Tongji Med Univ       Date:  2001

9.  A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.

Authors:  Andreas A Schnitzbauer; Carl Zuelke; Christian Graeb; Justine Rochon; Itxarone Bilbao; Patrizia Burra; Koert P de Jong; Christophe Duvoux; Norman M Kneteman; Rene Adam; Wolf O Bechstein; Thomas Becker; Susanne Beckebaum; Olivier Chazouillères; Umberto Cillo; Michele Colledan; Fred Fändrich; Jean Gugenheim; Johann P Hauss; Michael Heise; Ernest Hidalgo; Neville Jamieson; Alfred Königsrainer; Philipp E Lamby; Jan P Lerut; Heikki Mäkisalo; Raimund Margreiter; Vincenzo Mazzaferro; Ingrid Mutzbauer; Gerd Otto; Georges-Philippe Pageaux; Antonio D Pinna; Jacques Pirenne; Magnus Rizell; Giorgio Rossi; Lionel Rostaing; Andre Roy; Victor Sanchez Turrion; Jan Schmidt; Roberto I Troisi; Bart van Hoek; Umberto Valente; Philippe Wolf; Heiner Wolters; Darius F Mirza; Tim Scholz; Rudolf Steininger; Gunnar Soderdahl; Simone I Strasser; Karl-Walter Jauch; Peter Neuhaus; Hans J Schlitt; Edward K Geissler
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

10.  Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model.

Authors:  Lai-Chun Ong; In-Chin Song; Yi Jin; Irene H C Kee; Eeyan Siew; Sidney Yu; Choon-Hua Thng; Hung Huynh; Pierce K H Chow
Journal:  Mol Imaging Biol       Date:  2009-03-28       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.